TP53RK and cancer: The downregulation of PD-L1 observed in PRPK-deficient tumors aligns with broader findings in cancer immunology, where immune checkpoint molecules have been shown to dampen antitumor immunity (Dermani et al, 2019; Topalian et al, 2012; Wang and Wu, 2020).